JOURNAL OF
Periodontology

Future of preventing and managing common chronic inflammatory diseases

Kenneth S. Kornman (ID)

Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI

Correspondence
Kenneth S. Kornman, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, 1011 North University Avenue, Ann Arbor, MI 48109-1078.
Email: kkornman@umich.edu

Abstract

Chronic inflammation has emerged as a key factor that contributes to some common chronic diseases and reduces lifespan. Studies have identified multiple types of chronic inflammation ranging from autoimmune disease, which attacks specific tissues, to autoinflammatory diseases, which cause low-grade systemic inflammation and contribute to several common chronic diseases. This article highlights new perspectives on the role of chronic inflammation in cardiovascular disease (CVD). Such information is being leveraged to develop new treatment strategies for CVD and may inform how periodontal disease influences CVD.

KEYWORDS
cardiovascular disease, C-reactive protein, inflammation, inflammatory disease, periodontal disease, periodontitis

1 | CHRONIC INFLAMMATION AS A FACTOR IN CHRONIC DISEASES AND REDUCED LIFESPAN

A major change in the understanding of chronic inflammatory diseases occurred in the late 1990s. Fundamental to this change was research focused on the association between levels of low-grade systemic inflammation and cardiovascular disease (CVD) clinical outcomes.[1-5] These studies used high sensitivity C-reactive protein (hsCRP) analysis of blood samples as the indicator of systemic inflammation. CRP is one component of the acute phase responses that are produced by the liver in response to circulating cytokines, most commonly interleukin-6 (IL-6), IL-1β, and tumor necrosis factor alpha (TNFα). The concentration of hsCRP in the blood is an effective indicator of circulating pro-inflammatory cytokines arising from any inflamed tissue at the time of hsCRP measurement. Most hsCRP studies focused on prediction of CVD outcomes in response to interventions that reduced inflammation, as measured by changes in hsCRP.

Low density lipoprotein cholesterol (LDL-C) is accepted as a major causal factor for CVD and determinant of atherosclerotic events, although several modifying risk factors certainly influence disease expression. The systemic inflammation studies in recent years challenged the concept that CVD was primarily caused by LDL-C driven lipid accumulation on the arterial wall, which ultimately produced symptoms that required medication, surgical interventions, or both.[6] The early inflammation studies in CVD intervention provided evidence that reducing systemic inflammation was as protective against recurrent or initial major atherosclerotic events as was lowering LDL-C.[3,4,7]

During the same period, evidence emerged, primarily from genetic studies, to support the causality of another lipid factor, lipoprotein(a) [Lp(a)] in CVD.[8-11] The *LPA* gene, encoding Lp(a), is highly polymorphic, and its expression determines plasma levels of Lp(a) that vary among populations. Consequently, and in contrast to LDL-C, Lp(a) blood levels are not influenced by diet, exercise, or statins.

In parallel to the inflammation clinical trials, researchers were identifying a key role for IL-1β as a major driver of vascular inflammation and trigger of atherosclerotic events.[5,6,12-14] In a clinical study of patients

with CVD, the risk of coronary artery disease increased with blood levels of Lp(a) that were above the median, but primarily in patients with *IL1B* genetic patterns that lead to high expression of IL-1β protein. The subjects without genetic patterns that led to high IL-1β levels had minimal increased risk of coronary artery disease regardless of elevated Lp(a) level.[9,10,15-17]

Based on many studies implicating systemic inflammation and the role of IL-1β in CVD,[18-22] a 10,000-person randomized controlled trial tested if blocking inflammation with canakinumab, an antibody specifically targeting IL-1β, reduced the risk of cardiovascular events in a high-risk patient population.[5,22] The results were striking. Not only did blocking inflammation reduce the incidence of recurrent major cardiovascular events, but it also reduced the number of hospitalizations in patients with heart failure,[23] the incidence of lung cancer,[24] and the occurrence of major renal events in patients with chronic kidney disease.[25]

Another study implicated chronic systemic inflammation as a risk factor that prevents healthy aging. The "Hawaii Lifespan Study" is a longitudinal study of Japanese-American men born and living in Hawaii.[26] Survival analysis of this cohort of men found that indicators of low-grade chronic inflammation, such as higher concentrations of circulating fibrinogen or increased numbers of white blood cells, were associated with reduced survival. This chronic inflammation was one of only seven primary factors that prevented healthy aging. Thus, chronic inflammation is a key factor that contributes to both chronic disease risk and healthy aging.

2 | TYPES OF CHRONIC INFLAMMATORY DISEASE

Although the CVD studies increased awareness of chronic inflammatory diseases, such diseases are not a single entity. The most prevalent chronic inflammatory diseases, obesity and periodontitis, involve chronic continuing challenges. The chronic inflammation of obesity is driven by an overnutrition challenge, and a chronic interproximal bacterial challenge leads to most cases of periodontitis. Substantial new understanding about autoinflammatory and autoimmune diseases has emerged due in large part to classification of such diseases as a biologic continuum (Figure 1).[27,28]

The classic chronic inflammatory disease is often activated by an autoimmune process, such as in rheumatoid arthritis. These diseases have high levels of systemic inflammation, with circulating CRP concentrations that often exceed 10 mg/L.[29] Not only is there autoimmune destruction of local tissues, but there is also tissue damage that results from secondary inflammation caused by the

Autoinflammation

Rare monogenic autoinflammatory disease | Polygenic autoinflammatory diseases | Mixed pattern diseases | Polygenic autoimmune diseases | Rare monogenic autoimmune diseases

Autoimmunity

FIGURE 1 Inflammatory and autoimmune diseases are a continuum. Examples of rare monogenic autoinflammatory diseases include FMF (Familial Mediterranean Fever), CAPS (Cryopyrin-Associated Periodic Syndrome) and NOMID (Neonatal Onset Multisystem Inflammatory Disease). Examples of polygenic autoinflammatory diseases include Crohn's disease, ulcerative colitis, psoriatic arthritis, CVD. Examples of polygenic autoimmune diseases include Systemic Lupus Erythematosus, Type 1 diabetes, and rheumatoid arthritis. An example of a rare monogenic autoimmune disease is ALPS (autoimmune lymphoproliferative syndrome). Reprinted with permission from *Journal of Leukocyte Biology*[28]

autoimmune attack. There are >80 autoimmune diseases, which exhibit great variation among patients in terms of their severity. In all of these, the underlying issue is dysregulated immune tolerance to one's own tissues and subsequent inflammatory damage to local tissues. TNFα blocking agents, such as etanercept, have been very effective with several autoimmune diseases including rheumatoid arthritis, Crohn's Disease, psoriasis, and others.[30]

Autoinflammatory diseases represent another dimension of chronic inflammatory diseases. They were originally identified in patients that had unpredictable flares that produced symptoms, including fever, skin rashes, or joint swelling that were known to be initiated by innate immune mechanisms. Clinicians recognized that these presentations were rare and were ultimately identified as being caused by genetic mutations in biological mechanisms that regulated the innate immune response. It became clear that these rare autoinflammatory diseases were not autoimmune diseases involving antibodies that attacked the patient's healthy body tissues.

Some of these autoinflammatory diseases are rare monogenic diseases and others are quite common. Among the rare monogenic diseases are Familial Mediterranean Fever, Neonatal Onset Multisystem Inflammatory Disease, and Deficiency of Interleukin-1 Receptor Antagonist. These diseases are associated with rare mutations in inflammasome genes that lead to a dysregulated active caspase-1 that converts pro-IL-1β to active IL-1β. Such mutations result in high levels of IL-1β released to cause the symptom patterns associated with the rare monogenic autoinflammatory diseases. Anti-TNFα drugs are less effective for the

autoinflammatory diseases as opposed to the autoimmune diseases.

In contrast to the rare autoinflammatory diseases, there is emerging recognition and interest in more prevalent chronic inflammatory diseases that are in part driven by an imbalance of key cytokines, including IL-1β and IL-6, that drive innate immunity. These more common diseases driven by an imbalance of innate immunity do not display the intense episodes of acute inflammation, as described above for rare autoinflammatory diseases.[30] Both the rare forms of autoinflammatory disease and the more common forms are defined by increased inflammation involving cytokines of the innate immune system, more specifically IL-1β.

Atherosclerotic CVD is the most well-studied common disease in which increased risk for major clinical events is found in patients with persistent elevations of systemic inflammation, as defined by blood hsCRP, despite various drugs that produce substantial reductions in LDL cholesterol levels.[31] The systemic inflammatory challenge in chronic diseases can be from dysregulated metabolism as occurs in cancer and metabolic disorders, genetic factors, respiratory and skin irritants, and unresolved infections. These common autoinflammatory diseases are typically associated with excessive production of cytokines that activate amplifying cascades, in particular IL-1β or IL-6.[13,31,32] It is well established that once released, IL-1β self-activates its own gene expression through the IL-1 receptor I. The auto-stimulation has been shown in some clinical situations to be the result of an imbalance between the IL-1β agonist and the natural antagonist IL-1Ra, which has been demonstrated in Type 2 diabetes[33] and in progressive knee osteoarthritis.[34] The pathologic outcomes arise from amplifying cascades driven by cytokine-activated pathways.

A newer concept in chronic inflammatory diseases is that some common conditions do not have overt characteristics of inflammation and generally do not respond predictably to non-specific anti-inflammatory drugs,[5,21,31,35] yet these conditions have an essential inflammatory component that drives the pathology.[5,23,24,36] These are often common diseases in which low-grade chronic inflammation may be evident, but disease-initiating factors become the focus of preventing or managing the disease. Examples include diet-influenced saturated fats or high blood pressure as initiating factors in CVD;[5,6] smoking in lung cancer;[24] and physical trauma to a joint in osteoarthritis.[34,37] In those examples of common chronic diseases, there are activating factors that trigger inflammation control points, such as IL-1β, that drive multiple cascades that amplify or resolve inflammation at various stages. The inflammatory response is essential to health but depends on tightly controlled regulation. If the inflammation activators are too potent or prolonged, the downstream inflammatory mediators that make prostaglandins, vascular adhesion molecules, chemotaxins, hematopoietic factors, lymphocyte and tissue cell growth factors, and other cytokines, such as IL-6 and IL-8, can lead to disease and tissue damage. The evolving concepts of common autoinflammatory diseases are well characterized by extensive work on the role of low-grade systemic inflammation in cardiovascular disease events.[1,4,5]

These downstream inflammatory mediators then drive damage to arterial vessels in CVD, amplify destruction of pulmonary tissue in lung cancer, and destroy both connective tissue and bone in osteoarthritis. These common diseases with a chronic inflammatory component generally do not have an autoimmune component and are associated with low-grade circulating CRP (<10 mg/L). Indeed, in CVD, the increased risk for cardiovascular events has been associated with hsCRP levels exceeding 2 mg/L.[36]

Common chronic diseases also have an imbalance in inflammation that is evident as elevated hsCRP and, combined with inflammation activators, such as lipoprotein(a) or low-density lipoprotein cholesterol, produce a low-grade chronic inflammation. Such conditions have been recently validated in a randomized controlled clinical trial involving an IL-1β inhibitor (canakinumab).[5] Thus, chronic inflammation can contribute to common chronic diseases, such as CVD,[5] cancer,[24] and chronic kidney disease.[25] Both a secondary inflammatory response to tissue injury or the presence of an autoinflammatory condition can contribute to common chronic diseases that impact healthy aging, quality of life, and ultimately lifespan.

3 | TARGETING THE INFLAMMATORY COMPONENT OF CARDIOVASCULAR DISEASE

The evolution of observations and technologies that drove various concepts of pathogenesis of atherosclerosis since the 1800s has been richly described by Libby and Hansson.[6] The clinical evidence supports that at least two blood lipids, LDL-C and Lp(a), along with inflammatory mechanisms, produce atherosclerotic CVD that, in some individuals, results in Major Adverse Cardiovascular Events (MACE).

Recent clinical trials demonstrated that PCSK9 inhibitors achieved dramatic lowering of LDL-C beyond that attainable with intensive statin therapy and, as a result, strongly enhanced prevention of recurrent MACE.[38,39] An antisense drug targeting Lp(a) is also under investigation.[40] However, it will be a few years

FIGURE 2 New therapeutics from CVD studies that are poised to address common chronic inflammatory diseases. The left side represents drugs that specifically reduce CVD by targeting "residual cholesterol risk." The right side represents drugs that could reduce CVD and other chronic diseases associated with increased systemic inflammation by reducing "residual inflammatory risk." [Credit: Heather McDonald, BioSerendipity, LLC, Elkridge, MD]

before the results will show if this drug lowers Lp(a) sufficiently to reduce MACE. The development of MACE in individuals with elevated Lp(a) was conditional on the presence of an IL-1β genetic pattern that leads to high production of IL-1β protein.[16,17] In high risk CVD patients, drugs that specifically block IL-1β, but not less specific anti-inflammatory drugs, reduced MACE.[35]

With this appreciation of the role of inflammation as a key driver of CVD events, new treatment options have been and are being developed (Figure 2). These include blocking the lipids that trigger atherosclerosis and vascular inflammation. Such agents include inhibitors of PCSK9, a liver protein that promotes the degradation of LDL receptors which leads to higher cholesterol. The PCSK9 inhibitors block degradation of LDL receptors which reduces blood cholesterol. Even in patients already taking statins, PCSK9 inhibitors have dramatically reduced LDL-cholesterol and the risk of CVD events.[18,19] An antisense drug designed to specifically reduce Lp(a) is in Phase III clinical trials.[40]

If the initiating factors are not reduced or the patient fails to respond to such treatments, MACE can be reduced by blocking the key drivers of arterial inflammation, most prominently IL-1β. IL-1β must be activated by molecular complexes called inflammasomes. Thus, there are several

points at which IL-1β signaling can be inhibited: Drugs can target IL-1β itself, as with canakinumab,[22,24] drugs can inhibit the assembly of the inflammasome to block processing and release of IL-1β, or drugs can inhibit the induction of IL-1β by either blocking the intracellular signaling pathway or by preventing activation of the receptors that initiate IL-1β expression.

4 | IMPLICATIONS FOR TREATING PERIODONTAL DISEASE

Much of the clinical focus has been on systemic inflammation as a contributor to chronic disease. However, chronic diseases can also contribute to systemic inflammation, thereby connecting multiple chronic diseases through an inflammatory component. These inflammatory diseases include periodontitis, type 2 diabetes, obesity, and others. Indeed, obesity and periodontitis are among the most prevalent chronic inflammatory diseases and are risk factors for other chronic diseases (Figure 3).

Although periodontitis, as with CVD, does not exhibit the classic signs of rare autoinflammatory diseases including unpredictable fevers, skin rashes, and joint

FIGURE 3 Multiple factors contribute to an individual's systemic inflammatory burden. Studies using hsCRP as an indicator of systemic inflammation revealed that gender, ethnicity, genetics, smoking, diet, and lifestyle contribute to systemic inflammatory burden. Systemic inflammatory burden contributes to multiple chronic diseases and diseases associated with aging. Periodontal disease and obesity are common inflammatory diseases. By causing systemic inflammation, chronic inflammatory diseases contributed to increased risk of other chronic diseases. [Credit: Heather McDonald, BioSerendipity, LLC, Elkridge, MD]

damage, severe periodontitis is characterized by increased levels of IL-1β[41-45] and CRP,[46-48] which are consistent with other common autoinflammatory diseases.[49]

In recent years, investigators have used large clinical databases to ask whether the presence of a specific disease that increases systemic inflammation also increases the risk for future CVD or type 2 diabetes. One of the most impressive studies of this type used the UK clinical practice research database and identified >100,000 patients with diagnoses of specific types of chronic inflammatory diseases. They asked whether the presence of one or more of the chronic inflammatory diseases increased the risk for future coronary artery disease, stroke, or type II diabetes. They compared the frequency of these three diseases in individuals who had a chronic inflammatory disease and those that did not. There were >370,000 individuals who had no prior history of chronic inflammatory diseases and served as the reference population.[50] The investigators reported that individuals with a history

of chronic inflammatory disease and increased systemic inflammation had a 30% to 35% greater incidence of coronary artery disease, stroke, or type 2 diabetes compared to the reference group.

The studies of inflammation in chronic disease, which have used hsCRP as the indicator, have revealed many factors that influence systemic inflammatory burden (Figure 3). These factors include ethnicity, gender, smoking, polymorphisms in genes involved in inflammation, diet, and other environmental factors. These factors increase systemic inflammatory burden, which then contributes to chronic diseases, including rheumatoid arthritis, Alzheimer's disease, type 2 diabetes, coronary artery disease, obesity, and moderate to advanced periodontitis. The current challenge is identifying which individuals with chronic inflammatory diseases, such as periodontitis, have increased systemic inflammation that alters the course of other chronic diseases including CVD and Type 2 diabetes. Systemic inflammation is a central player

that connects periodontitis to multiple chronic diseases of aging.

5 | CONCLUSION

Although there are many studies that show an independent association between moderate to severe periodontitis and coronary artery disease and strokes, there are no direct intervention studies that show treatment of specific cases of periodontitis reduce MACE. It is reasonable, however, to propose establishing salivary and blood biomarkers to objectively assess treatment outcomes of periodontitis that may include decreases in systemic biomarkers that have been shown to reduce both first and recurrent CVD events as a first step. It is likely that the knowledge gained from the study of systemic inflammation in CVD and other chronic diseases will inform new treatment strategies for periodontal disease.

DISCLOSURES
Dr. Kornman is an officer of Sitokine Ltd., London, UK. Sitokine has patents covering genetic patterns that increase production of IL-1β and increase risk for various chronic diseases but has no patents related to periodontal disease. Dr. Kornman currently serves as editor-in-chief of the *Journal of Periodontology*.

ORCID
Kenneth S. Kornman https://orcid.org/0000-0003-2252-7324

REFERENCES
1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med*. 2000;342:836-843.

2. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation*. 2003;107:363-369.

3. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med*. 2005;352:20-28.

4. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195-2207.

5. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377:1119-1131.

6. Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. *J Am Coll Cardiol*. 2019;74:1594-1607.

7. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. *Am Heart J*. 2004;148:S19-S26.

8. Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? *J Lipid Res*. 2016;57:745-757.

9. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. *N Engl J Med*. 2005;353:46-57.

10. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res*. 2016;57:1953-1975.

11. Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. *J Am Coll Cardiol*. 2018;71:177-192.

12. Libby P. Molecular bases of the acute coronary syndromes. *Circulation*. 1995;91:2844-2850.

13. Libby P, Loscalzo J, Ridker PM, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. *J Am Coll Cardiol*. 2018;72:2071-2081.

14. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. *J Clin Invest*. 1986;78:1432-1438.

15. Tsimikas S. A test in context: lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. *J Am Coll Cardiol*. 2017;69:692-711.

16. Naka KK, Bechlioullis A, Marini A, et al. Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. *J Clin Lipidol*. 2018;12:338-347.

17. Tsimikas S, Duff GW, Berger PB, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). *J Am Coll Cardiol*. 2014;63:1724-1734.

18. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. *Circulation*. 2003;108:1664-1672.

19. Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? *Trans Am Clin Climatol Assoc*. 2013;124:174-190.

20. Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? *Curr Atheroscler Rep.* 2013;15:295.

21. Ridker PM. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2018;72:3320-3331.

22. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). *Am Heart J.* 2011;162:597-605.

23. Everett BM, Cornel JH, Lainscak M, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. *Circulation.* 2019;139:1289-1299.

24. Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet.* 2017;390:1833-1842.

25. Ridker PM, MacFadyen JG, Glynn RJ, et al. Inhibition of interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. *J Am Coll Cardiol.* 2018;71:2405-2414.

26. Bell CL, Chen R, Masaki K, et al. Late-life factors associated with healthy aging in older men. *J Am Geriatr Soc.* 2014;62:880-888.

27. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. *PLoS Med.* 2006;3:e297.

28. Chetaille Nezondet AL, Poubelle PE, Pelletier M. The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases. *J Leukoc Biol.* 2020.

29. Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. *Semin Arthritis Rheum.* 1994;24:91-104.

30. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. *Nat Rev Drug Discov.* 2012;11:633-652.

31. Aday AW, Ridker PM. Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease. *Front Cardiovasc Med.* 2019;6:16.

32. Libby P. Interleukin-1 Beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. *J Am Coll Cardiol.* 2017;70:2278-2289.

33. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. *J Clin Invest.* 2002;110:851-860.

34. Wu X, Kondragunta V, Kornman KS, et al. IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort. *Osteoarthritis Cartilage.* 2013;21:930-938.

35. Ridker PM. Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials. *J Intern Med.* 2019;285:503-509.

36. Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J.* 2018;39:3499-3507.

37. DiCesare PE, Abramson SB. Pathogenesis of osteoarthritis. In: Harris DE, Budd RC, Genovese MC, Firestein GS, Sargeni JS, Sledge CB, eds. *Kelly's Textbook of Rheumatology.* New York, NY: Elsevier Saunders; 2005:1493-1513.

38. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med.* 2017;376:1713-1722.

39. Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. *JAMA Cardiol.* 2019;4:613-619.

40. Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet.* 2016;388:2239-2253.

41. Hajishengallis G, Lamont RJ, Graves DT. The enduring importance of animal models in understanding periodontal disease. *Virulence.* 2015;6(3):229-235.

42. Graves DT, Oates T, Garlet GP. Review of osteoimmunology and the host response in endodontic and periodontal lesions. *J Oral Microbiol.* 2011;3.

43. Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. *J Periodontol.* 2003;74:391-401.

44. Delima AJ, Karatzas S, Amar S, Graves DT. Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists. *J Infect Dis.* 2002;186:511-516.

45. Cheng R, Wu Z, Li M, Shao M, Hu T. Interleukin-1beta is a potential therapeutic target for periodontitis: a narrative review. *Int J Oral Sci.* 2020;12:2.

46. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. *J Clin Periodontol.* 2008;35:277-290.

47. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. *J Periodontol.* 2001;72:1221-1227.

48. Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. *J Periodontol.* 2000;71:1528-1534.

49. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. *Eur J Immunol.* 2011;41:1203-1217.

50. Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. *Circulation.* 2014;130:837-844.